Characterization of novel PI3Kδ inhibitors as potential therapeutics for SLE and lupus nephritis in pre-clinical studies

Frontiers in Immunology

Volumn 5, Issue MAY, 2014, Pages

  Haselmayer, Philipp ^a   Camps, Montserrat ^b   Muzerelle, Mathilde ^b,e   Bawab, Samer El ^a   Waltzinger, Caroline ^b,f   Bruns, Lisa ^a   Abla, Nada ^b   Polokoff, Mark A ^c   Jond Necand, Carole ^b   Gaudet, Marilène ^b   Benoit, Audrey ^b   Meier, Dominique Bertschy ^b   Martin, Catherine ^b   Gretener, Denise ^b   Lombardi, Maria Stella ^b,g   Grenningloh, Roland ^d   Ladel, Christoph ^a   Petersen, Jørgen Søberg ^b,h   Gaillard, Pascale ^b,i   Ji, Hong ^b,h  

^a Merck Serono GmbH   (Germany)

^b MERCK SERONO S A   (Switzerland)

^c DiscoveRx Corporation   (United States)

^d EMD Serono Research Institute   (United States)

^e Debiopharm Research and Manufacturing SA   (Switzerland)

^f Roche Glycart AG   (Switzerland)

^g UNIVERSITY OF GENEVA   (Switzerland)

^h NOVO NORDISK A S   (Denmark)

ⁱ ALAXIA SAS   (France)

Author keywords

Drug development; Immune response; Lupus nephritis; Pharmacodynamic biomarker; Pharmacokinetic pharmacodynamic modeling; PI3K inhibitor; SLE

Indexed keywords

6 FLUORO 3 (MORPHOLIN 4 YLCARBONYL) 1 [4 (MORPHOLIN 4 YLMETHYL)PHENYL] 1,4 DIHYDROTHIOCHROMENO[4,3 C]PYRAZOLE5,5 DIOXIDE; 7 FLUORO 3 (MORPHOLIN 4 YLCARBONYL) 1 [1 (2 MORPHOLIN 4 YLETHYL)PIPERIDIN 3 YL] 1,4 DIHYDROTHIOCHROMENO[4,3 C]PYRAZOLE5,5 DIOXIDE; ADENOVIRUS VECTOR; ALPHA INTERFERON; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN D ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MSC2360844; MSC2364588; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BIOASSAY; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; CROSS LINKING; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; KIDNEY FIBROSIS; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; PHARMACODYNAMICS; PLASMACYTOID DENDRITIC CELL; PROTEIN PHOSPHORYLATION; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; UPREGULATION;

EID: 84905497024     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00233     Document Type: Article

References (39)

1. Tsokos GC. Systemic lupus erythematosus. N Engl J Med (2011) 365:2110-21. doi:10.1056/NEJMra1100359
2. Ortega LM, Schultz DR, Lenz O, Pardo V, Contreras GN. Review: lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. Lupus (2010) 19:557-74. doi:10.1177/0961203309358187
3. Boyce EG, Fusco BE. Belimumab: review of use in systemic lupus erythematosus. Clin Ther (2012) 34:1006-22. doi:10.1016/j.clinthera.2012.02.028
4. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem (2001) 70:535-602. doi:10.1146/annurev.biochem.70.1.535
5. Hirsch E, Ciraolo E, Ghigo A, Costa C. Taming the PI3K team to hold inflammation and cancer at bay. Pharmacol Ther (2008) 118:192-205. doi:10.1016/j.pharmthera.2008.02.004
6. Okkenhaug K, Fruman DA. PI3Ks in lymphocyte signaling and development. Curr Top Microbiol Immunol (2010) 346:57-85. doi:10.1007/82_2010_45
7. Guiducci C, Ghirelli C, Marloie-Provost MA, Matray T, Coffman RL, Liu YJ, et al. PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. J Exp Med (2008) 205:315-22. doi:10.1084/jem.20070763
8. Suarez-Fueyo A, Barber DF, Martinez-Ara J, Zea-Mendoza AC, Carrera AC. Enhanced phosphoinositide 3-kinase delta activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death. J Immunol (2011) 187:2376-85. doi:10.4049/jimmunol.1101602
9. Maxwell MJ, Tsantikos E, Kong AM, Vanhaesebroeck B, Tarlinton DM, Hibbs ML. Attenuation of phosphoinositide 3-kinase delta signaling restrains autoimmune disease. J Autoimmun (2012) 38:381-91. doi:10.1016/j.jaut.2012.04.001
10. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J, et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med (2005) 11:936-43. doi:10.1038/nm1284
11. Berg EL, Yang J, Melrose J, Nguyen D, Privat S, Rosler E, et al. Chemical target and pathway toxicity mechanisms defined in primary human cell systems. J Pharmacol Toxicol Methods (2010) 61:3-15. doi:10.1016/j.vascn.2009.10.001
12. Berg EL, Yang J, Polokoff MA. Building predictive models for mechanism-of-action classification from phenotypic assay data sets. J Biomol Screen (2013) 18:1260-9. doi:10.1177/1087057113505324
13. Melton AC, Melrose J, Alajoki L, Privat S, Cho H, Brown N, et al. Regulation of IL-17A production is distinct from IL-17F in a primary human cell co-culture model of T cell-mediated B cell activation. PLoS One (2013) 8:e58966. doi:10.1371/journal.pone.0058966
14. Kunkel EJ, Plavec I, Nguyen D, Melrose J, Rosler ES, Kao LT, et al. Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models. Assay Drug Dev Technol (2004) 2:431-41. doi:10.1089/adt.2004.2.431
15. Kunkel EJ, Dea M, Ebens A, Hytopoulos E, Melrose J, Nguyen D, et al. An integrative biology approach for analysis of drug action in models of human vascular inflammation. FASEB J (2004) 18:1279-81. doi:10.1096/fj.04-1538fje
16. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science (2002) 297:1031-4. doi:10.1126/science.1073560
17. Crispin JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE, et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol (2008) 181:8761-6. doi:10.4049/jimmunol.181.12.8761
18. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A (2003) 100:2610-5. doi:10.1073/pnas.0337679100
19. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med (2003) 197:711-23. doi:10.1084/jem.20021553
20. Foster MH. Relevance of systemic lupus erythematosus nephritis animal models to human disease. Semin Nephrol (1999) 19:12-24.
21. Mathian A, Gallegos M, Pascual V, Banchereau J, Koutouzov S. Interferon-alpha induces unabated production of short-lived plasma cells in pre-autoimmune lupus-prone (NZBxNZW)F1 mice but not in BALB/c mice. Eur J Immunol (2011) 41:863-72. doi:10.1002/eji.201040649
22. Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity (2003) 36:511-8. doi:10.1080/08916930310001605873
23. Liu Z, Bethunaickan R, Huang W, Ramanujam M, Madaio MP, Davidson A. IFN-alpha confers resistance of systemic lupus erythematosus nephritis to therapy in NZB/W F1 mice. J Immunol (2011) 187:1506-13. doi:10.4049/jimmunol.1004142
24. Wang Y, Ito S, Chino Y, Goto D, Matsumoto I, Murata H, et al. Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis. Clin Exp Immunol (2010) 159:1-10. doi:10.1111/j.1365-2249.2009.04031.x
25. Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol (2009) 10:778-85. doi:10.1038/ni.1741
26. Hsu HC, Yang P, Wang J, Wu Q, Myers R, Chen J, et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol (2008) 9:166-75. doi:10.1038/ni1552
27. Brkic Z, Corneth OB, van Helden-Meeuwsen CG, Dolhain RJ, Maria NI, Paulissen SM, et al. T helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus? Arthritis Res Ther (2014) 16:R62. doi:10.1186/ar4499
28. Hahn BH. Antibodies to DNA. N Engl J Med (1998) 338:1359-68. doi:10.1056/NEJM199805073381906
29. Kiefer K, Oropallo MA, Cancro MP, Marshak-Rothstein A. Role of type I interferons in the activation of autoreactive B cells. Immunol Cell Biol (2012) 90:498-504. doi:10.1038/icb.2012.10
30. Le BA, Thompson C, Kamphuis E, Durand V, Rossmann C, Kalinke U, et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol (2006) 176:2074-8. doi:10.4049/jimmunol.176.4.2074
31. Croker JA, Kimberly RP. SLE: challenges and candidates in human disease. Trends Immunol (2005) 26:580-6. doi:10.1016/j.it.2005.09.001
32. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum (2004) 50:2580-9. doi:10.1002/art.20430
33. Clayton E, Bardi G, Bell SE, Chantry D, Downes CP, Gray A, et al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med (2002) 196:753-63. doi:10.1084/jem.20020805
34. Golding A, Hasni S, Illei G, Shevach EM. The percentage of FoxP3+Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus. Arthritis Rheum (2013) 65:2898-906. doi:10.1002/art.38119
35. Miyara M, Gorochov G, Ehrenstein M, Musset L, Sakaguchi S, Amoura Z. Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmun Rev (2011) 10:744-55. doi:10.1016/j.autrev.2011.05.004
36. Patton DT, Garden OA, Pearce WP, Clough LE, Monk CR, Leung E, et al. Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J Immunol (2006) 177:6598-602. doi:10.4049/jimmunol.177.10.6598
37. Bueters T, Ploeger BA, Visser SA. The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives. Drug Discov Today (2013) 18:853-62. doi:10.1016/j.drudis.2013.05.001
38. Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, et al. PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol (2013) 20:1364-74. doi:10.1016/j.chembiol.2013.09.017
39. Wang Y, Zhang L, Wei P, Zhang H, Liu C. Inhibition of PI3Kdelta improves systemic lupus in mice. Inflammation (2014). doi:10.1007/s10753-014-9818-0